Preoperative conversion therapy of camrelizumab combined with paclitaxel and nedaplatin for unresectable advanced esophageal squamous cell carcinoma: a phase 2 study.

ABSTRACT:

Background

Patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC) face limited treatment options and poor outcomes. Preclinical evidence supports chemoimmunotherapy as a conversion therapy; therefore, this study aims to evaluate the efficacy and safety of preoperative camrelizumab with paclitaxel and nedaplatin.

Methods

Patients received a combination of camrelizumab (200 mg), paclitaxel (155 mg/m²), and nedaplatin (80 mg/m²) every 3 weeks. An efficacy assessment was performed every two cycles using the RECIST v1.1 criteria, and patients in the resected group underwent surgery 4-6 weeks after the last dose. The primary endpoint was 1-year overall survival (OS) rate, while secondary endpoints included surgical conversion ra

SUBMITTER: Zhu J 

PROVIDER: S-EPMC12857139 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature